Differential expression of 12 histone deacetylase (<it>HDAC</it>) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas
<p>Abstract</p> <p>Background</p> <p>Glioblastoma is the most lethal primary malignant brain tumor. Although considerable progress has been made in the treatment of this aggressive tumor, the clinical outcome for patients remains poor. Histone deacetylases (HDACs) are r...
Main Authors: | Lucio-Eterovic Agda KB, Cortez Maria AA, Valera Elvis T, Motta Fabio JN, Queiroz Rosane GP, Machado Helio R, Carlotti Carlos G, Neder Luciano, Scrideli Carlos A, Tone Luiz G |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-08-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/8/243 |
Similar Items
-
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022-01-01) -
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
by: Sharma, N, et al.
Published: (2013) -
Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
by: Beatriz Silva Urias, et al.
Published: (2022-10-01) -
Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
by: Min Young Kim, et al.
Published: (2020-11-01) -
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
by: Yuxiang Luo, et al.
Published: (2020-11-01)